tradingkey.logo

Third Harmonic Bio Inc

THRD

5.380USD

-0.005-0.09%
Horarios del mercado ETCotizaciones retrasadas 15 min
241.86MCap. mercado
PérdidaP/E TTM

Third Harmonic Bio Inc

5.380

-0.005-0.09%
Más Datos de Third Harmonic Bio Inc Compañía
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
Información de la empresa
Símbolo de cotizaciónTHRD
Nombre de la empresaThird Harmonic Bio Inc
Fecha de salida a bolsaSep 15, 2022
Director ejecutivo- -
Número de empleados53
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 15
Dirección1700 Montgomery Street
CiudadSAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94111
Teléfono12097272457
Sitio Webhttps://thirdharmonicbio.com/
Símbolo de cotizaciónTHRD
Fecha de salida a bolsaSep 15, 2022
Director ejecutivo- -
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Gladstone
Mr. Michael Gladstone
Independent Director
Independent Director
--
--
Mr. Thomas M. Soloway
Mr. Thomas M. Soloway
Independent Director
Independent Director
--
--
Dr. H. Martin Seidel, Ph.D.
Dr. H. Martin Seidel, Ph.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Geoff Mcdonough, M.D.
Dr. Geoff Mcdonough, M.D.
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Christopher M. Murphy
Mr. Christopher M. Murphy
Chief Financial and Business Officer and Principal financial officer
Chief Financial and Business Officer and Principal financial officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Gladstone
Mr. Michael Gladstone
Independent Director
Independent Director
--
--
Mr. Thomas M. Soloway
Mr. Thomas M. Soloway
Independent Director
Independent Director
--
--
Dr. H. Martin Seidel, Ph.D.
Dr. H. Martin Seidel, Ph.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Geoff Mcdonough, M.D.
Dr. Geoff Mcdonough, M.D.
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 1 de ago
Actualizado: vie., 1 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Atlas Venture
23.05%
OrbiMed Advisors, LLC
12.81%
BML Capital Management LLC
8.47%
Nantahala Capital Management, LLC
6.51%
Novartis AG
5.86%
Other
43.30%
Accionistas
Accionistas
Proporción
Atlas Venture
23.05%
OrbiMed Advisors, LLC
12.81%
BML Capital Management LLC
8.47%
Nantahala Capital Management, LLC
6.51%
Novartis AG
5.86%
Other
43.30%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
23.05%
Investment Advisor
22.10%
Hedge Fund
16.18%
Private Equity
12.81%
Corporation
5.94%
Investment Advisor/Hedge Fund
4.55%
Individual Investor
3.18%
Research Firm
1.75%
Pension Fund
0.11%
Other
10.36%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
211
40.27M
89.23%
-16.78M
2025Q1
212
42.91M
95.09%
-14.37M
2024Q4
195
49.11M
108.99%
-3.57M
2024Q3
188
48.20M
116.40%
-5.90M
2024Q2
179
44.41M
107.54%
-7.00M
2024Q1
168
42.07M
102.65%
-7.97M
2023Q4
157
42.10M
104.28%
-7.14M
2023Q3
134
41.90M
103.75%
-2.52M
2023Q2
124
40.16M
99.46%
-3.19M
2023Q1
118
40.99M
101.62%
+118.50K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Atlas Venture
10.40M
23.05%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
5.78M
12.81%
--
--
Mar 31, 2025
BML Capital Management LLC
3.82M
8.47%
+100.25K
+2.69%
Mar 31, 2025
Nantahala Capital Management, LLC
2.94M
6.51%
+2.44M
+486.57%
Mar 31, 2025
Novartis AG
2.64M
5.86%
--
--
Mar 31, 2025
TCG Crossover Management, LLC
2.51M
5.55%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.32M
2.92%
+6.37K
+0.49%
Mar 31, 2025
Holles Natalie C
1.22M
2.7%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.16M
2.57%
+129.61K
+12.58%
Mar 31, 2025
Tang Capital Management, LLC
929.73K
2.06%
+779.73K
+519.82%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
Ver más
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
iShares Micro-Cap ETF
Proporción0.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI